Background {#Sec1}
==========

Microglia change both morphologically and functionally from their resting state to their activated state in several neuroinflammatory and neurodegenerative diseases. Thus, microglial activation accompanies damage to the brain environment and is a reason why activated microglia represent an important marker of neuroinflammation \[[@CR1]\]. Specifically, non-invasive imaging of activated microglia is a useful tool for detecting in vivo neuroinflammatory disease. To date, the first-generation translocator protein 18 kDa (TSPO) marker (*R*)-\[^11^C\]PK11195 has been widely used as a PET radioligand for this purpose. PET studies using (*R*)-\[^11^C\]PK11195 have been performed on patients with several neuroinflammatory diseases, including Alzheimer's disease (AD) \[[@CR2]\], Parkinson's disease (PD) \[[@CR3]\], and Huntington's disease \[[@CR4]\]. In addition, ischemic stroke causes direct insults to the brain tissue and the immediate activation of microglia, which can also be visualized by PET with (*R*)-\[^11^C\]PK11195 \[[@CR5]\]. PET imaging provides an experimental advantage in that it allows studies on time-course changes in microglial activation. Specifically, as neuronal loss is a common feature of neuronal degeneration, acute neuronal damage, and aging, an early depiction of the extent to which the brain is compromised is important for treatment to delay the progression of such disease processes. In this context, techniques to image neuroinflammation in vivo, such as TSPO-PET, are helpful because no other imaging method exists to evaluate neuroinflammation in the living brain. It is currently well reported that the accumulation of (*R*)-\[^11^C\]PK11195 or the second-generation tracer \[^18^F\]DPA714 occurs relatively late after brain injury resulting from toxin injection \[[@CR6]\] or traumatic insult \[[@CR7], [@CR8]\].

Endocannabinoid receptor type 2 (CB2) has recently been considered to be an alternative method for targeting activated microglia using PET imaging. The endocannabinoid system in the central nervous system has been shown to provide neuroprotective effects following brain injury \[[@CR9], [@CR10]\]. In particular, CB2 is upregulated in microglia during neurodegenerative and neuroinflammatory diseases such as AD \[[@CR11]--[@CR13]\], multiple sclerosis \[[@CR14]\], PD \[[@CR15]\], and ischemia \[[@CR16]--[@CR19]\], and is also known to be associated with microglial activity \[[@CR20]\]. Moreover, the administration of a selective CB2 agonist reduced neuronal degeneration and improved cognitive function scores \[[@CR11], [@CR21]\]. Recently, a PET tracer that binds specifically to CB2 was developed to illustrate CB2 availability in vivo \[[@CR22]\]. Considering that the neuroprotective role of microglia develops early in the course of brain illness, the failure to detect elevated \[^11^C\]NE40 uptake in AD patients \[[@CR23]\] is understandable, possibly because the microglia activated during the chronic state of neurodegeneration are considered to be acting as proinflammatory cells \[[@CR24]\] or because the demise of neurons that also express CB2 reduces detectable radioactivity. Recently, we reported that \[^11^C\]NE40 binding is increased in the peri-infarct area of the ipsilateral cortex at 24 h after induction of stroke, but not in the contralateral cortex, using a photothrombotic stroke model \[[@CR25]\]. Following CB2 activation, uptake of a TSPO tracer is observed at the chronic stage, indicating that different inflammatory responses of microglia occur in the acute and chronic states after ischemia \[[@CR26]\]. This early activation of CB2 might also be observed in a variety of animal models of neurological disorders such as AD, multiple sclerosis, and amyotrophic lateral sclerosis \[[@CR27]\]. However, it is unclear whether CB2 is upregulated in animal models of senescence or early-stage mild cognitive impairment.

SAMPs (senescence-accelerated mouse prones) are inbred mouse lines showing accelerated aging. Of these, the SAMP10 line shows neuronal loss due to cortical degeneration in later life. It has been reported that SAMP10 mice show impaired conditioning memory with elevation of serum corticosterone at 12 weeks of age when they are chronically exposed to social isolation stress from 5 weeks of age \[[@CR28]\]. In addition, they are likely to show significant reductions in cortical size from 7 months old because of neuronal loss \[[@CR29]\]. In later stages at 8--16 months of age, not only the number of neurons, but also the length of dendrites and the spine density of cortical pyramidal neurons, are much reduced \[[@CR30]\]. Behavioral changes related to neuronal dysfunction, such as decline of performance in passive avoidance and conditional avoidance tasks, also occurred in mice aged 10 to 12 months \[[@CR29]\]. Interestingly, morphological impairments in microglia occurred at an early stage (\~ 3 months old), preceding age-related neuronal degeneration \[[@CR31]\], with the number of segments and tips and the combined lengths of microglial processes being much reduced. Hence, we aimed to investigate the status of microglia by comparing 5-week-old SAMP10 mice with 15-week-old animals, to detect early responses of microglia to brain aging.

In this study, we used PET to compare the levels of \[^11^C\]NE40 and (*R*)-\[^11^C\]PK11195 binding in the same living SAMP10 mice at different ages, because SAMP10 mice are suitable for evaluating the early response of microglia in terms of polarization around the timing of senescence-related microglial activation. The in vivo PET data were then corroborated by performing immunohistochemical analysis for CB2 and TSPO.

Methods {#Sec2}
=======

Animals {#Sec3}
-------

Eight 5-week-old and eight 15-week-old male senescence-accelerated mouse prone 10 (SAMP10) mice purchased from the SLC Company (Hamamatsu, Japan) were used in this study. The mice were housed with their littermates maximum of five animals in each cage with food and water available ad libitum. All animals were grouped in each cage. The fact that no individual animal was isolated did not allow evaluation of neuroinflammatory responses under social isolation in this study.

All animal protocols and the following experiments were approved by the ethics committees of the Central Research Laboratory at Hamamatsu Photonics and Hamamatsu University School of Medicine. In addition, all applicable institutional and/or national guidelines for the care and use of animals were followed.

Tracer production {#Sec4}
-----------------

The synthesis of (*R*)-\[^11^C\]PK11195 was based on the literature \[[@CR32], [@CR33]\]. Briefly, \[^11^C\]CH~3~I was produced from \[^11^C\]CO~2~ or \[^11^C\]CH~4~ generated by irradiating N~2~ with protons in the presence of 0.2% O~2~ or 5% H~2~. Then, \[^11^C\]CH~3~I was reacted with desmethyl (*R*) PK11195 to form (*R*)-\[^11^C\]PK11195. The synthesis of \[^11^C\]NE40 was based on the literature \[[@CR34]\]. Briefly, a helium stream containing \[^11^C\]CH~3~I was bubbled through 200 μl dimethylformamide containing 200 μg 2-oxo-7-hydroxy-8-butyloxy-1,2-dihydroquinoline-3-carboxylic acid cyclohexylamide and 2--4 mg Cs~2~CO~3~ \[[@CR32]--[@CR34]\].

PET measurements {#Sec5}
----------------

PET measurements were acquired on a high-resolution animal PET scanner (SHR-38000, Hamamatsu Photonics, Hamamatsu, Japan) with an axial field of view (FOV) of 330 mm, a transaxial FOV of 108 mm, and a transaxial spatial resolution of 2.3 mm in the center. Eight animals were scanned twice a day with (*R*)-\[^11^C\]PK11195 and \[^11^C\]NE40. A 2-h interval was left between the two scans, and the order of the scans was counterbalanced. The mice were anesthetized using 1.5--2.0% isoflurane in O~2~ for the duration of the entire imaging experiment. The mice were placed in the prone position on a fixation plate and then set within the gantry hole of the PET scanner. After a 15-min transmission scan utilizing an external ^68^Ge/^68^Ga rod source (67 MBq) for attenuation correction, a serial emission scan lasting for 60 min was performed immediately following each injection of (*R*)-\[^11^C\]PK11195 or \[^11^C\]NE40 tracer at a dose of 48 MBq/kg; the tracers were injected intravenously through a cannula inserted into the tail vein. The molar activity of each tracer was above 50 GBq/μmol. No arterial sampling was conducted. The PET data were reconstructed using 3D DRAMA (iteration 2, gamma 0.1) with a Gaussian filter of 1.0 mm full width at half maximum (FWHM), yielding a voxel size of 0.65 × 0.65 × 1.0167 mm for the reconstructed images. To obtain anatomical information, X-ray CT scans were performed immediately following the PET measurement, using a ClairvivoCT (Shimadzu Corporation, Kyoto, Japan).

Data analysis and statistics {#Sec6}
----------------------------

Using PMOD image analysis software (version 3.1; PMOD Technologies Ltd., Zurich, Switzerland), the standard uptake value ratios (SUVRs) for (*R*)-\[^11^C\]PK11195 and \[^11^C\]NE40 tracer binding were estimated by dividing the target SUV by the cerebellar SUV as the background level \[[@CR35], [@CR36]\]. The SUV was calculated as the measured radioactivity divided by the ratio of the total injected dose to the mouse body weight.

As described elsewhere \[[@CR37], [@CR38]\], elliptical regions of interest (ROIs) ranging from 12 to 24 mm^2^ in area were placed over the frontal cortex and hippocampus regions by referring to the X-ray CT images \[[@CR39]\] (see Additional file [1](#MOESM1){ref-type="media"}: Figure S1).

One-way analysis of variance (ANOVA) was performed to compare the conditions (brain region, tracer uptake, and mouse age), with the significance level set at *p* \< 0.05 with a correction for multiple comparisons. Within each age group, correlation analysis was conducted between the two tracer SUVRs (\[^11^C\]NE40 SUVR vs. (*R*)-\[^11^C\]PK11195 SUVR at either 5 or 15 weeks of age) with the Bonferroni correction for multiple correlations (*p* \< 0.00625, 0.05/8), to examine deviations in the expression of these markers in the living brains of SAMP10 mice in relation to the progression of senescence.

Immunohistochemistry {#Sec7}
--------------------

Immunostaining was performed as previously reported \[[@CR40]\]. Briefly, mice were anesthetized with chloral hydrate (400 mg/kg) and then transcardially perfused with saline followed by 4% paraformaldehyde (PFA; pH 7.4). Their brains were removed, post-fixed in 4% PFA, and immersed in cryoprotectant solution (30% sucrose in phosphate-buffered saline \[PBS\]) until the tissue sank. Tissues were frozen in dry ice and stored at − 80 °C until use. Frozen coronal sections (20 μm thick) were cut using a cryostat. The slides were blocked with 10% donkey serum in PBS containing 0.1% Triton X-100 for 1 h at room temperature (RT) and then incubated overnight at 4 °C with primary antibodies. After washing, the slides were incubated for 1 h at RT with secondary antibodies. Then, they were washed three times with PBS and stained with DAPI to visualize the nuclei. Fluorescent images of a single focal plane were obtained by confocal microscopy (SP8, Leica, Wetzlar, Germany). The following primary antibodies were used in this study: goat anti-Iba1 (1:500, Abcam, Cambridge, UK), mouse anti-ATPB (1:200, Abcam), rabbit and mouse anti-cannabinoid receptor 2 (1:200, Cayman Chem, Ann Arbor, USA, and 1:200, Santa Cruz, Dallas, USA, respectively), rabbit anti-CaMKII (1:500, Abcam), mouse anti-GFAP (1:500, Merck Millipore, Burlington, USA), and rabbit anti-TSPO (1:200, Abcam). The secondary antibodies were as follows: Alexa Fluor 488 anti-rabbit IgG and anti-mouse IgG, Alexa Fluor 568 anti-rabbit IgG, Alexa Fluor 594 anti-mouse IgG, and Alexa Fluor 647 anti-goat IgG (1:500, Thermo Fisher Scientific, Waltham, USA).

Results {#Sec8}
=======

PET findings {#Sec9}
------------

Figure [1](#Fig1){ref-type="fig"} shows the parametric PET images of \[^11^C\]NE40 and (*R*)-\[^11^C\]PK11195 uptake superimposed on CT images for 5-week-old (a) and 15-week-old (b) mice. The SUVRs of \[^11^C\]NE40 and (*R*)-\[^11^C\]PK11195 did not significantly differ in the cerebral cortex and hippocampus in 5-week-old SAMP10 mice (Figs. [1](#Fig1){ref-type="fig"}a and [2](#Fig2){ref-type="fig"}a, Table [1](#Tab1){ref-type="table"}). By contrast, in 15-week-old SAMP10 mice, an ANOVA with multiple comparisons revealed a significantly higher SUVR for \[^11^C\]NE40 than for (*R*)-\[^11^C\]PK11195 in the frontal cortex (*F* = 5.062, *p* = 0.0119; Fig. [2](#Fig2){ref-type="fig"}b) and a tendency toward a higher \[^11^C\]NE40 SUVR in the hippocampus (*p* \< 0.07; Figs. [1](#Fig1){ref-type="fig"}b and [2](#Fig2){ref-type="fig"}b, Table [1](#Tab1){ref-type="table"}). The \[^11^C\]NE40 SUVR was not significantly higher in 15-week-old mice than in 5-week-old mice (Table [1](#Tab1){ref-type="table"}, Additional file [1](#MOESM1){ref-type="media"}: Figure S1C). Fig. 1Coronal parametric PET images of \[^11^C\]NE40 and (*R*)-\[^11^C\]PK11195 tracers in 5-week-old (**a**) and 15-week-old (**b**) SAMP10 mice. The PET data are superimposed on X-ray CT images, and the color bar denotes the SUVR Fig. 2The SUVRs of \[^11^C\]NE40 and (*R*)-\[^11^C\]PK11195 SUVR (**a**, **b**) and their relationships (**c**, **d**). The \[^11^C\]NE40 SUVR was significantly higher than the (*R*)-\[^11^C\]PK11195 SUVR in the cerebral cortex in 15-week-old mice (**b**, \**p* \< 0.05). The binding of the two tracers showed a positive correlation at 5 weeks of age (**c**). The dotted lines in **c** represent the 95% confidence intervals for the correlation. Dagger indicates a tendency for significant difference (*p* \< 0.07) Table 1Differences in the levels of SUVR of \[^11^C\]NE40 and \[^11^C\] (*R*)PK11195Age\[^11^C\]NE40\[^11^C\] (*R*)PK11195Cerebral cortexHippocampusCerebral cortexHippocampus 5 weeks1.18 ± 0.371.07 ± 0.230.85 ± 0.210.86 ± 0.21 15 weeks1.41 ± 0.43\*^a^1.24 ± 0.38^b^0.89 ± 0.160.94 ± 0.19\**p* \< 0.05 vs cerebral cortex \[^11^C\](*R*)PK11195 value (Tukey's multiple comparisons test)Tendency for significant difference (^a^*p* = 0.08, ^b^*p* = 0.10) vs 5-week-old mice data in \[^11^C\]NE40 measurement

Significant correlations were found between \[^11^C\]NE40 SUVRs and (*R*)-\[^11^C\]PK11195 SUVRs measured in the brains of 5-week-old mice (*r* = 0.501, *p* = 0.006; Fig. [2](#Fig2){ref-type="fig"}c), whereas no significant correlations were found in either 15-week-old SAMP10 mice (Fig. [2](#Fig2){ref-type="fig"}d) or 15-week-old SAMPR1 mice (*r* = 0.409, *p* = 0.117; Additional file [2](#MOESM2){ref-type="media"}: Figure S2B). In Additional file [2](#MOESM2){ref-type="media"}: Figure S2, data from 15-week-old SAMR1 mice (senescence-accelerated mouse resistant mice, the normal control for SAMP10 mice) are shown to help understand the changes seen in SAMP10 mice.

Immunohistochemical findings {#Sec10}
----------------------------

Double immunostaining against CB2 and the microglial marker Iba1 at 5 weeks of age revealed CB2 immunopositive signals across the whole brain region, including the cerebral cortex and hippocampus (Fig. [3](#Fig3){ref-type="fig"}). The CB2 signals were not colocalized with Iba1 in the cortex and hippocampus, suggesting that CB2 is expressed on neurons and/or astrocytes. At 15 weeks, the intensity and number of CB2-positive signals were dramatically increased in the cortex and hippocampus of the SAMP10 mice (Fig. [3](#Fig3){ref-type="fig"}a and b, respectively). Interestingly, the CB2-positive signal was colocalized with Iba1+ microglia in both the cortex and hippocampus at 15 weeks, suggesting that the number of protective microglia increases in the early stage of senescence-related neurodegeneration. In addition, CB2-positive signals were observed in CAMKII+ neurons and GFAP+ astrocytes in the cortex and hippocampus, respectively. This result is consistent with the observations of the PET imaging using the \[^11^C\]NE40 tracer, as shown in Fig. [1](#Fig1){ref-type="fig"}b. Fig. 3Double immunostaining for CB2 (green) and Iba1, CaMKII, or GFAP (red) in the cortex (**a**) and hippocampus (**b**) at 5 and 15 weeks of age. Note that the CB2 signal is greatly increased and localized to the microglia at 15 weeks of age. Arrowheads indicate CB2 signals in microglial cells. Scale bar 10 μm

In Fig. [4](#Fig4){ref-type="fig"}, triple immunostaining for TSPO (18 kDa), mitochondrial marker ATPB, and Iba1 shows detection of TSPO immunoreactive signal in the cerebral cortex and hippocampus at 5 weeks (Fig. [4](#Fig4){ref-type="fig"}a, b); hence, the TSPO signal is colocalized with ATPB and TSPO is located in the mitochondria at this age. The basal level of TSPO expression was mainly observed in the mitochondria of vascular endothelial cells, as previously reported (data not shown) \[[@CR41]\]. Confocal imaging analysis revealed punctuate TSPO immunopositive staining along with Iba1+ cells in the hippocampus (Fig. [4](#Fig4){ref-type="fig"}b). However, this staining was not located inside or on the surface of the Iba1+ cells, but was localized to the contact sites of adjacent cells, indicating the accumulation of TSPO on the microglial facing side. In Fig. [4](#Fig4){ref-type="fig"} c and d, TSPO signal can be detected inside the microglia in the cerebral cortex and hippocampus at 15 weeks. However, the overall intensity of the TSPO signal was not different to that in the 5-week-old mice and was consistent with the result of the PET imaging using the (*R*)-\[^11^C\]PK11195 tracer (Fig. [2](#Fig2){ref-type="fig"}b). This result suggests that the number of inflammatory microglia had not changed at this stage. Fig. 4Triple immunostaining for TSPO (green), ATPB (red), and Iba1 (yellow) in the cortex (**a**, **c**) and hippocampus (**b**, **d**) areas at 5 (**a**, **b**) and 15 weeks of age (**c**, **d**). Arrowheads indicate TSPO signals in microglial cells. Scale bar 10 μm

Discussion {#Sec11}
==========

Detection of microglial activation using the CB2 and TSPO tracers {#Sec12}
-----------------------------------------------------------------

In this study, we show that the SUVRs of \[^11^C\]NE40 were significantly higher than those of (*R*)-\[^11^C\]PK11195 in the cerebral cortical region in 15-week-old SAMP10 mice (Figs. [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}b; Additional file [1](#MOESM1){ref-type="media"}: Figure S1C, D). Although there was no significant difference, the SUVRs of \[^11^C\]NE40 of 15-week-old mice tended to be higher than those of 5-week-old mice. Along similar lines, CB2 expression in microglia was increased in the cerebral cortex and hippocampus in the 15-week-old mice in comparison with the 5-week-old mice (Fig. [3](#Fig3){ref-type="fig"}a, b). However, (*R*)-\[^11^C\]PK11195 did not reveal significantly higher TSP binding in 15-week-old SAMP10 mice (Fig. [2](#Fig2){ref-type="fig"}b). To our knowledge, this is the first time that microglial activation has been shown in vivo using PET imaging of SAMP10 mice. SAMP10 mice show neuronal loss after 7 months and cognitive impairment from 12 months of age \[[@CR29]\]. Prior to neurodegeneration, a morphological change to the microglia occurs in SAMP10 mice at 3 months of age \[[@CR31]\]. Our observation of an increase in the protective microglial marker CB2 at this stage, but not in the inflammatory microglial marker TSPO, is indicative of the neuroinflammatory phenomena characteristic of the early stage of neuronal degeneration.

Activation of protective microglia {#Sec13}
----------------------------------

The relatively rapid response of protective microglia extrapolated from the \[^11^C\]NE40 binding elevation suggests that the microglia try to maintain and/or recover the homeostasis of the brain environment; they may do this by engulfing degenerating neuronal debris or by releasing protective cytokines and/or neurotrophic factors such as interleukin (IL)-4, IL-10, BDNF, and IGF-1 \[[@CR42]\]. However, these processes are not successful in the SAMP10 mice, and eventually, neuronal degeneration occurs, causing behavioral impairment and cognitive deficits. From the therapeutic point of view, the targeting of CB2 activation or other pharmacological treatments that can revitalize protective microglia might present new opportunities for therapies to prevent neuronal loss and cognitive impairment. As CB2 expression is limited to specific types of cells like microglia, and in this way differs from the broad expression of CB1 in the central nervous system, any psychoactive effect of cannabinoids should be minimal. In line with our hypothesis, administration of the selective agonist JWH-015 to CB2 significantly enhanced phagocytosis of Aβ~1-42~, which was inhibited by CD40 \[[@CR43]\]. Additionally, the CD40 expression of microglial cells induced by IFN-γ was reduced by JWH-015 \[[@CR43]\]. Furthermore, the CB1/CB2 mixed agonist WIN55,212-2 improved memory functions and decreased levels of inflammatory marker TNF-α and caspase-3 activation in an Aβ-induced neurodegeneration model in adult rats \[[@CR44]\]. As SAMP10 mice exhibit senile amyloidosis at a late stage, these agonists might ameliorate their decline in cognitive function \[[@CR45]\].

TSPO and inflammatory microglia {#Sec14}
-------------------------------

TSPO is a highly inducible protein localized on the mitochondrial outer membrane upon microglial activation by inflammatory environment. In the healthy brain, endogenous TSPO expression is mainly observed in endothelial cells throughout the brain (data not shown) \[[@CR41]\]. This endothelial expression was also observed by immunostaining in our SAMP10 mice at both 5 and 15 weeks of age. Therefore, the basal level of (*R*)-\[^11^C\]PK11195 binding should represent the endothelial expression of TSPO. We also observed TSPO signal that was non-overlapping with the mitochondrial outer-membrane marker ATPB, as previously reported, which suggests TSPO localization in subcellular organelles other than mitochondria \[[@CR46]\]. It is also known that, upon inflammation, TSPO is expressed not only in microglia, but also in astrocytes \[[@CR47], [@CR48]\]. In the SAMP10 mice, as the TSPO level was not enhanced at 15 weeks, it is probable that the level of TSPO in astrocytes was also not enhanced. The inflammatory IL-6 level is reportedly increased at 14 months; therefore, TSPO would probably be upregulated at the later stage of brain degeneration \[[@CR49]\]. This speculation is consistent with our previous finding that uptake of (*R*)-\[^11^C\]PK11195 is high at a later period after stroke in a rat model \[[@CR35]\].

In the chronic stage of inflammation \[[@CR6]\], neurotoxic M1-phenotype microglia are dominant, and the TSPO tracer (*R*)-\[^11^C\]PK11195 reflects inflammatory rather than anti-inflammatory microglial activity \[[@CR24]\]. In support of this assertion, we showed an elevation in the second-generation TSPO tracer \[^11^C\]DPA713 for illustrating chronically activated microglia under inflammatory circumstances \[[@CR50]\]. We recently used a photochemically induced thrombosis (PIT) model to show that the CB2 response occurs earlier than the TSPO response \[[@CR25]\]. This suggests that the activation of protective microglia is the key event and that this occurs prior to inflammatory microglial activation in the case of neuronal damage.

Limitations {#Sec15}
-----------

This study is subject to a number of limitations. First, we measured changes in the uptake of both \[^11^C\]NE40 and (*R*)-\[^11^C\]PK11195 in 5- and 15-week-old SAMP10 mice. These data do not allow us to elucidate the timing of the state switch, dominancy, protective activity, or inflammatory processes of microglia. Later stage SAMP10 mice might generate different outcomes with regard to inflammatory substances and cells \[[@CR49]\], and further study is needed to address changes in the time course of inflammatory events during senescence-related neuronal loss. Second, because the spatial resolution of the PET scanner used was only 2.3 mm, the results may be subject to partial volume effects. To reduce such effects, we tried to set the measurement ROIs to twice the size of the FWHM of the scanner. An alternative would be to use autoradiography instead of PET, although measures of parameter changed in the same animal cannot be obtained using autoradiography. In this study, we therefore used the cerebellum as a non-specific region for CB2/TSPO expression to estimate the specific binding of the tracers, which is a widely accepted method.

Conclusion {#Sec16}
==========

The detected increase in \[^11^C\]NE40 binding but not (*R*)-\[^11^C\]PK11195 binding in 15-week-old SAMP10 mice, which was concomitant with a higher CB2 immunochemical expression within the microglia, indicates that acutely activated microglia may be involved in a neuroprotective process of neuroinflammation in the early stage of senescence-related neuronal loss. While the new CB2 tracer \[^11^C\]A836339 has been reported to exceed the sensitivity of \[^11^C\]NE40 for in vivo binding to CB2 under a chronic state of neurodegeneration \[[@CR13]\], the present results suggest that \[^11^C\]NE40 might be adequate for depicting activated microglia in the very early stage of brain disorders.

Our results provide in vivo evidence of different responses of two types of microglia to senescence-accelerated neuroinflammation, implying the perturbation of microglial balance by aging. Specific treatment that stimulates CB2-positive microglia or expression of CB2 in microglia to promote neuroprotection might help ameliorate senescence-related neuroinflammation.
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 {#Sec17}

**Additional file 1:Figure S1.** CT images and regions of interest in the cerebral cortex (A, yellow, approximately −1 mm from the bregma) and hippocampus (B, red, approximately −2 mm from the bregma). The PET data are rearranged according to each tracer to demonstrate the changes across all groups (C, D). Cbx: cerebral cortex, Hip: hippocampus; 5w: 5 weeks of age; 15w: 15 weeks of age. †a tendency (*p*=0.08) vs 5-week-old mice data in \[^11^C\]NE40 measurement. **Additional file 2:Figure S2.** The SUVRs of the two tracers did not significantly differ in 15-week-old SAMR1 mice (A). The correlation between the SUVRs of the two tracers failed to reach statistical significance (*p* = 0.117, *r* = 0.409) (B). \[^11^C\]NE40 uptake was found significantly higher in 15-week old SAMP10 mice than in 15-week-old SAMR1 mice.

(*R*)-\[^11^C\]PK11195

:   (*R*)-N-(11) C-methyl-N-(1-methylpropyl)-1(2-chlorophenyl) isoquinoline-3-carboxamide

^11^C-DPA713

:   N,N-diethyl-2-\[2-(4-methoxyphenyl)-5,7-dimethylpyrazolo \[1,5-a\]pyrimidin-3-yl\] acetamide

^11^C-NE40

:   2-oxo-7-\[11C\]methoxy-8butyloxy-1,2-dihydroquinoline-3-carboxylic acid cyclohexylamide

AD

:   Alzheimer's disease
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:   Type 2 endocannabinoid receptor

FWHM

:   Full width at half maximum

PET

:   Positron emission tomography

PFA

:   Paraformaldehyde

R1

:   Tracer influx index

RT

:   Room temperature

SAMP

:   Senescence-accelerated mouse prone

SUVR

:   Standard uptake value ratio

TSPO

:   Translocator protein
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